1. This includes standards for flame retardant performance to IEC 60332-1, another key characteristic to consider.   How can Avient help?  

Office Supplies Pet Care & Supplies Auto-injectors and Drug Delivery Pens

Changes will continue to be made in our data which will come both from our vast supply base as well as from global chemical and toxicity data used in determining GHS classifications. Distributors have until December 1, 2015 to implement the same changes. Complete implementation for suppliers and employers will be required by December 1, 2018.

Factors that could cause actual results to differ materially from those implied by these forward looking statements include but are not limited to:• Factors that could cause actual results to differ materially from those implied by these forward‐looking statements include, but are not limited to:  Our ability to achieve the strategic and other objectives relating to the Spartech acquisition, including any expected synergies; our ability to successfully  integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;  Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and  cost of credit in the future;  The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate  liquidity) to maintain their credit availability;liquidity) to maintain their credit availability;  The speed and extent of an economic recovery, including the recovery of the housing market;  Our ability to achieve new business gains;  The amount and timing of repurchases, if any, of PolyOne common shares and our ability to pay regular quarterly cash dividends and the amounts and  timing of any future dividends;  The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;  Changes in polymer consumption growth rates in the markets where we conduct business;g p y p g ;  Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;  Fluctuations in raw material prices, quality and supply and in energy prices and supply;  Production outages or material costs associated with scheduled or unscheduled maintenance programs;  Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;  An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital  reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;, , p y p y g , y p p ;  An inability to maintain appropriate relations with unions and employees; and  Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and  changes in the rate of inflation. • The above list of factors is not exhaustive. • We undertake no obligation to publicly update forward‐looking statements, whether as a result of new information, future events or otherwise.   Page 3 Strategy and Execution Drive Results 90% $22 $24 PolyOne Stock Price 50% $18 $20 $22 S&P 500 (relative performance) 30% $12 $14 $16 S&P 500 (relative performance) ‐10% 10% $6 $8 $10 50% ‐30% $0 $2 $4 $ | ‐50%$0 2006 2007 2008 2009 2010 2011 2012 2013 Page 4 Four Pillar Strategy The World’s Premier Provider of SpecializedThe World s Premier Provider of Specialized  Polymer Materials, Services & Solutions Page 5 Spartech – Compelling Strategic Rationale • Spartech expands PolyOne’s specialty portfolio with adjacent  technologies in attractive end markets  Bolt on acquisition with opportunity for global expansion as only Bolt‐on acquisition with opportunity for global expansion, as only  6% of Spartech’s revenues are outside of North America • PolyOne has a proven management team with a track record of  transformational success • Preliminary synergy estimated at $65 million run rate by end of  3year 3  Significant opportunity to expand profitability by leveraging  PolyOne’s four pillar strategy • Substantial potential share price appreciation for all  shareholders f f ll / $ Accretive to EPS in first full year post‐acquisition / $0.50 once  synergies realized Page 6 Mix Shift Highlights Specialty Transformation  Old  PolyOne Transformation 100% 2015 Target 80% In co m e*   65 – 75%40% 60% f O pe ra tin g  34% 43% 45% 65  75% 20%  o f 2%0% 2005 2008 2010 2012 2015 Specialty OI $5M   $46M                        $87M                       $114M                     Target *Operating Income excludes corporate charges and special items JV's PP&S Distribution Specialty Page 7 Proof of Performance 2007 2012 2015 “Where we were” “Where we are” “Where we Where we were Where we are expect to be" 1)  Operating Income % Specialty 3.2% 9.1% 12 – 16% PP&S 6.1% 9.0% 9 – 12% Distribution 3.0% 6.4% 6 – 7.5% 2)  Specialty Platform sss% of Operating Income 20% 45% 65 – 75% 3) ROIC* ( ft t ) 7% 11% 15%3) ROIC* (after‐tax) 7% 11% 15% 4)  Adjusted EPS Growth** N/A 4 yr CAGR = 55% Double Digit  Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period **4 yr EPS CAGR calculated using 2012 adjusted EPS vs 2008 adjusted EPS Page 8 Proof of Performance Spartech Opportunity Intermediate  PolyOne Spartech Opportunity 2006 2012 Today Goal “Where we were” “Where we are” “Where  Spartech is”* “Where we can go”were are Spartech is can go Specialty Operating Margin 1.5% 9.1% 2.2% 8.0% – 10.0%  Margin Page 9 *Pro Forma results include Spartech corporate allocations for FY12 ended November 3, 2012 PolyOne 14% Latin America 3% Distribution 2012 Revenues: $4.2 Billion* 2012 Revenues: $4.2 Billion* United States 14% 5% PP&S 20%Specialty 57% Building & HealthCare 1.02 1.20 $1.20 $1.40 ha re End Markets* EPS Growth Construction 14% 17% Industrial 9% 0.27 0 21 0.79 $0.40 $0.60 $0.80 $1.00 Ad ju st ed  E ar ni ng s P er  S Electrical & 0.12 0.21 0.13 $0.00 $0.20 2006 2007 2008 2009 2010 2011 2012 Page 10 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Specialty U it d 2012 Revenues: $2.4 Billion* Solutions United States 59% 9% Latin America Building & C t ti HealthCare   o f S al es 12-16% End Markets* Expanding Profits Construction Electrical & Industrial 15% 1.5% 3.2% 4.3% 5.3% 8.4% 9.1% O pe ra tin g  In co m e  Page 11 2006 2007 2008 2009 2010 2011 2012 2015 O Target* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Designed Structures and Solutions United States 2012 Revenues: $0.85 Billion* Solutions 84% Latin America 4% Building & Construction Sign & Advertising 3% Recreation & Leisure Pool & Spa 1% Distribution & Thermoform 2% Operating Income % of Sales 2012 Revenue by Industry Segment* Expanding Profits** Electrical & Electronics 23%Industrial 3% 2.2% 8 ‐ 10% 1% HealthCare 2012 2015 Target  Page 12 *Pro Forma includes FY2012 results for Spartech (11/03/12 YE) **Pro Forma results include Spartech corporate allocations for FY12 Positioned for Earnings Growth 2015 Target Rev: $5B Adj.  EPS: $1.20 Proforma Debt Maturities & Liquidity Summary – 12/31/12 (Reflecting  Financing & Spartech Acquisition) • Total Debt at 12/31/12 h $1,010 $297 $360 $300 $400 Debt Maturities  As of December  31, 2012  ($ millions) Less: Cash Net Debt 213 $797 $50 $297 $100 $200 • Available Liquidity Cash $213 $800 Debt Maturities  As of December  31, 2012 P f f 2/13 Fi i $50 $0 2015 2017 2020 Interest Rates: 7.500%                       5.000%                      7.375% Cash ABL Availability Total Liquidity $213 271 $484 $600 $400 $600 Proforma for 2/13 Financing ($ millions) Total Liquidity • Net Debt / EBITDA = 2.0x* $484 $50 $360 $0 $200 • Net Debt / EBITDA = 2.35x** $50$0 2015 2020 2023 Page 14 Interest Rates:   7.500%                      7.375%                      5.250% *Assumes $65 million of synergies related to Spartech acquistion **Assumes no synergies related to Spartech acquistion Use of Cash Share DividendsOrganic G Acquisitions • Repurchased 1 2 Repurchase • Introduced a Dividends • Expanding our Growth T t th t d Acquisitions • Repurchased 1.2 million shares in 2012 • 20.0 million shares are il bl f • Introduced a quarterly dividend in Q1 2011 and increased in Q1 2012 (25%) and Q1 2013 (20%) • Expanding our sales, marketing, and technical capabilities is top priority • Investing in • Targets that expand our: • Specialty offering • End market presence • Geographic footprint available for repurchase under the current authorization Q1 2013 (20%) • Objective of maintaining and growing Investing in operational and LSS initiatives (including synergy capture) • CAPEX • Synergy opportunities • Adjacent material solutions Proforma Cash Balance = $213M N t D bt / EBITDA* 2 0X CAPEX Net Debt / EBITDA* = 2.0X *Adjusted EBITDA assumes synergies related to the Spartech acquisition are realized at close; preliminary synergies estimated at $65M and are expected to be achieved over a 3-year period Page 15 Why Invest In PolyOne?

• FIBER-LINE® packing yarn are designed to improve the performance versus finished braid coatings, yielding time and cost savings. • Coating at the filament level allows the various resins to penetrate the fiber bundle before the yarn are braided.  Packaging FIBER-LINE® Packing Yarn are supplied on a variety of cardboard tubes to meet your equipment needs. Packages can be supplied on colored, embossed and/or slit tubes.

Creative and effective use of polymer colorants can have an effect all along the value chain, from brand recognition to competitive differentiation and a greater emotional connection with the product.

Pride at Avient RAISE at Avient Supplier Collaboration & Evaluation

An enforced gap analysis of technical documentation may show that current plastic resin grades or masterbatches do not have adequate change control, and there are insufficient change agreements with suppliers With a broad portfolio of healthcare polymer technologies under the Mevopur™ brand, Avient can assist in addressing many of these challenges. Learn more about Avient solutions for the healthcare market:

Plastic Bank® was the chosen supplier of the PCR content. Their collection communities collect and exchange ocean-bound plastic waste as currency for income and life-improving benefits, including health, work, and life insurance, digital connectivity, grocery vouchers, school supplies, fintech services, and more. THE SOLUTION Working with Plastic Bank, Avient expedited its approval as a new supplier, reducing Hager’s project timeline.

Handling Ultimate UV is supplied as a liquid dispersion which offers convenient, accurate and consistent dosing from minimal product addition. Wavelength (nm) – C93 Control 5 – Ultimate UV390-1 @ 0.15% 1 – UV390R 3 90 80 70 60 50 40 30 20 10 0 300 350 400 450 500 550 600 650 700 Tr an sm is si on (% ) 1.844.4AVIENT www.avient.com Copyright © 2023, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.